239 related articles for article (PubMed ID: 28244200)
1. Population pharmacokinetics of recombinant coagulation factor VIII-SingleChain in patients with severe hemophilia A.
Zhang Y; Roberts J; Tortorici M; Veldman A; St Ledger K; Feussner A; Sidhu J
J Thromb Haemost; 2017 Jun; 15(6):1106-1114. PubMed ID: 28244200
[TBL] [Abstract][Full Text] [Related]
2. Comparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products.
Simpson ML; Desai V; Maro GS; Yan S
J Manag Care Spec Pharm; 2020 Apr; 26(4):504-512. PubMed ID: 32020842
[TBL] [Abstract][Full Text] [Related]
3. Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII.
Zollner S; Raquet E; Claar P; Müller-Cohrs J; Metzner HJ; Weimer T; Pragst I; Dickneite G; Schulte S
Thromb Res; 2014 Jul; 134(1):125-31. PubMed ID: 24814969
[TBL] [Abstract][Full Text] [Related]
4. Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate(®) ) in patients with severe haemophilia A.
Klamroth R; Simpson M; von Depka-Prondzinski M; Gill JC; Morfini M; Powell JS; Santagostino E; Davis J; Huth-Kühne A; Leissinger C; Neumeister P; Bensen-Kennedy D; Feussner A; Limsakun T; Zhou M; Veldman A; St Ledger K; Blackman N; Pabinger I
Haemophilia; 2016 Sep; 22(5):730-8. PubMed ID: 27434619
[TBL] [Abstract][Full Text] [Related]
5. A French Real-World Evidence Study Evaluating the Efficacy, Safety, and Pharmacokinetic Parameters of rVIII-SingleChain in Patients with Hemophilia A Receiving Prophylaxis.
Guillet B; Hassoun A; Wibaut B; Harroche A; Biron-Andréani C; Repesse Y; d'Oiron R; Tardy B; Pan Petesch B; Chamouni P; Gay V; Fouassier M; Pouplard C; Martin C; Catovic H; Delavenne X
Thromb Haemost; 2023 May; 123(5):490-500. PubMed ID: 36758611
[TBL] [Abstract][Full Text] [Related]
6. Safety, efficacy and pharmacokinetics of rVIII-SingleChain in children with severe hemophilia A: results of a multicenter clinical trial.
Stasyshyn O; Djambas Khayat C; Iosava G; Ong J; Abdul Karim F; Fischer K; Veldman A; Blackman N; St Ledger K; Pabinger I
J Thromb Haemost; 2017 Apr; 15(4):636-644. PubMed ID: 28166608
[TBL] [Abstract][Full Text] [Related]
7. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII.
Zollner SB; Raquet E; Müller-Cohrs J; Metzner HJ; Weimer T; Pragst I; Dickneite G; Schulte S
Thromb Res; 2013 Aug; 132(2):280-7. PubMed ID: 23830969
[TBL] [Abstract][Full Text] [Related]
8. A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients.
Yan S; Maro GS; Desai V; Simpson ML
J Manag Care Spec Pharm; 2020 Oct; 26(10):1258-1265. PubMed ID: 32820685
[TBL] [Abstract][Full Text] [Related]
9. Analysis of pooled real-world data from Germany, Italy, and the United States of rVIII-SingleChain compared with standard- and long-acting FVIII products for prophylaxis of hemophilia A.
Olivieri M; Simpson M; Yan S; Fedorovsky J; Zhang X; Tomic R; Pinachyan K; Mancuso ME
Curr Med Res Opin; 2022 Jul; 38(7):1133-1139. PubMed ID: 35387548
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A.
Mahlangu J; Kuliczkowski K; Karim FA; Stasyshyn O; Kosinova MV; Lepatan LM; Skotnicki A; Boggio LN; Klamroth R; Oldenburg J; Hellmann A; Santagostino E; Baker RI; Fischer K; Gill JC; P'Ng S; Chowdary P; Escobar MA; Khayat CD; Rusen L; Bensen-Kennedy D; Blackman N; Limsakun T; Veldman A; St Ledger K; Pabinger I;
Blood; 2016 Aug; 128(5):630-7. PubMed ID: 27330001
[TBL] [Abstract][Full Text] [Related]
11. Impact of capacity-limited binding on recombinant factor VIII and von Willebrand factor pharmacokinetics in hemophilia A rats.
Vargas Christensen I; Loftager M; Rode F; Mørck Nielsen H; Kreilgaard M; Larsen MS
J Thromb Haemost; 2019 Jun; 17(6):964-974. PubMed ID: 30924607
[TBL] [Abstract][Full Text] [Related]
12. Assessing prophylactic use and clinical outcomes in hemophilia A patients treated with rVIII-SingleChain and other common rFVIII products in Germany.
Olivieri M; Sommerer P; Maro G; Yan S
Eur J Haematol; 2020 Apr; 104(4):310-317. PubMed ID: 31883398
[TBL] [Abstract][Full Text] [Related]
13. Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A.
Bonanad S; Núñez R; Poveda JL; Kurnik K; Goldmann G; Andreozzi V; Vandewalle B; Santos S
Adv Ther; 2021 Sep; 38(9):4872-4884. PubMed ID: 34368918
[TBL] [Abstract][Full Text] [Related]
14. Lonoctocog alfa (rVIII-SingleChain) for the treatment of haemophilia A.
Raso S; Hermans C
Expert Opin Biol Ther; 2018 Jan; 18(1):87-94. PubMed ID: 29256333
[TBL] [Abstract][Full Text] [Related]
15. Recombinant full-length factor VIII (FVIII) and extended half-life FVIII products in prophylaxis--new insight provided by pharmacokinetic modelling.
Gringeri A; Wolfsegger M; Steinitz KN; Reininger AJ
Haemophilia; 2015 May; 21(3):300-306. PubMed ID: 25643824
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B.
Zhang Y; Roberts J; Bensen-Kennedy D; Jacobs I; Santagostino E; Voigt C; Feussner A; Morfini M; Sidhu J
J Thromb Haemost; 2016 Nov; 14(11):2132-2140. PubMed ID: 27513989
[TBL] [Abstract][Full Text] [Related]
17. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.
Shapiro AD; Ragni MV; Kulkarni R; Oldenberg J; Srivastava A; Quon DV; Pasi KJ; Hanabusa H; Pabinger I; Mahlangu J; Fogarty P; Lillicrap D; Kulke S; Potts J; Neelakantan S; Nestorov I; Li S; Dumont JA; Jiang H; Brennan A; Pierce GF
J Thromb Haemost; 2014 Nov; 12(11):1788-800. PubMed ID: 25196897
[TBL] [Abstract][Full Text] [Related]
18. Increased potency of recombinant VWF D'D3 albumin fusion proteins engineered for enhanced affinity for coagulation factor VIII.
Chia J; Pestel S; Glauser I; Emmrich K; Hardy MP; Mischnik M; Raquet E; Tomasetig V; Claar P; Zalewski A; Bass GT; Turnbull V; Chen CG; Wilson MJ; Panousis C; Weimer T; Andrews A; Verhagen AM; Dower SK
J Thromb Haemost; 2021 Nov; 19(11):2710-2725. PubMed ID: 34333849
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of recombinant factor VIII Fc fusion protein.
Nestorov I; Neelakantan S; Ludden TM; Li S; Jiang H; Rogge M
Clin Pharmacol Drug Dev; 2015; 4(3):163-74. PubMed ID: 27140796
[TBL] [Abstract][Full Text] [Related]
20. Italian experience with rVIII-single chain: a survey of patients with haemophilia A and their physicians.
Borchiellini A; Castaman G; Feola G; Ferretti A; Giordano P; Luciani M; Malcangi G; Margaglione M; Molinari AC; Pollio B; Rocino A; Santoro C; Schiavulli M; Zanon E
J Thromb Thrombolysis; 2022 May; 53(4):934-944. PubMed ID: 34775566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
